Study objectives were to assess the efficacy, safety, and tolerability of @entity42863 in @entity191 @entity1 with levodopa-induced @entity910 . Two randomized, double-blind, placebo-controlled, parallel-group, in- @entity1 studies for @entity191 @entity1 with moderate to severe levodopa-induced @entity910 (study 1) and severe levodopa-induced @entity910 (study 2) on stable dopaminergic therapy were performed. @entity1 received 25-150 mg @entity42863 or placebo twice daily for 16 days (both studies). Study 2 included a 4-day down-titration. Primary outcomes were the Lang-Fahn Activities of Daily Living @entity910 Scale (study 1), the modified @entity910 Scale (study 2), and the Unified @entity191 Rating Scale-part III (both studies). Secondary outcomes included the Unified @entity191 Rating Scale-part IV items 32-33. The primary analysis was change from baseline to day 16 on all outcomes. Treatment differences were assessed. Fifteen @entity1 were randomized to @entity42863 and 16 to placebo in study 1; 14 @entity1 were randomized to each group in study 2. @entity42863 -treated @entity1 showed significant improvements in @entity910 on day 16 versus placebo (eg, Lang-Fahn Activities of Daily Living @entity910 Scale, P = .021 [study 1]; modified @entity910 Scale, P = .032 [study 2]). No significant changes were seen from baseline on day 16 on the Unified @entity191 Rating Scale-part III in either study. Adverse events were reported in both studies, including dizziness. Serious adverse events (most commonly worsening of @entity910 , apparently associated with stopping treatment) were reported by 4 @entity42863 -treated @entity1 in study 1, and 3 @entity1 (2 @entity42863 -treated @entity1 and 1 in the placebo group) in study 2. @entity42863 showed a clinically relevant and significant antidyskinetic effect without changing the antiparkinsonian effects of dopaminergic therapy.    2011 @entity717 Society.

XXXX treatment of levodopa-induced @entity910 : results of 2 randomized controlled trials.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity910 :: ('MESH:D004409', 'Disease') :: ['dyskinesia', 'dyskinesias', 'Abnormal Involuntary Movement', 'Dyskinesia'] @entity42863 :: ('MESH:C581397', 'Chemical') :: ['AFQ056'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", "Parkinson's Disease"] @entity717 :: ('MESH:D009069', 'Disease') :: ['Movement Disorder']
@entity42863 :: (MESH:C581397,Chemical) :: ['AFQ056']
